4.5 Article

Mortality from adverse drug reactions in adult medical inpatients at four hospitals in South Africa: a cross-sectional survey

Journal

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Volume 80, Issue 4, Pages 818-826

Publisher

WILEY
DOI: 10.1111/bcp.12567

Keywords

adverse drug reaction; antiretroviral therapy; anti-tuberculosis therapy; in-hospital death; preventability; South Africa

Funding

  1. Centers for Disease Control and Prevention (CDC)
  2. President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC) [GGH000371]

Ask authors/readers for more resources

AimsFatal adverse drug reactions (ADRs) are important causes of death, but data from resource-limited settings are scarce. We determined the proportion of deaths in South African medical inpatients attributable to ADRs, and their preventability, stratified by human immunodeficiency virus (HIV) status. MethodsWe reviewed the folders of all patients who died over a 30 day period in the medical wards of four hospitals. We identified ADR-related deaths (deaths where an ADR was possible', probable' or certain' using WHO-UMC criteria and where the ADR contributed to death). We determined preventability according to previously published criteria. ResultsADRs contributed to the death of 2.9% of medical admissions and 56 of 357 deaths (16%) were ADR-related. Tenofovir, rifampicin and co-trimoxazole were the most commonly implicated drugs. 43% of ADRs were considered preventable. The following factors were independently associated with ADR-related death: HIV-infected patients on antiretroviral therapy (adjusted odds ratio (aOR) 4.4, 95% confidence interval (CI) 1.6, 12), exposure to more than seven drugs (aOR 2.5, 95% CI 1.3, 4.8) and increasing comorbidity score (aOR 1.3, 95% CI 1.1, 1.7). ConclusionsIn our setting, where HIV and tuberculosis are highly prevalent, fatal in-hospital ADRs were more common than reported in high income settings. Most deaths were attributed to drugs used in managing HIV and tuberculosis. A large proportion of the ADRs were preventable, highlighting the need to strengthen systems for health care worker training and support.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Pharmacology & Pharmacy

Drug-drug interaction between rifabutin and dolutegravir: A population pharmacokinetic model

Aida N. N. Kawuma, Roeland E. E. Wasmann, Kelly E. E. Dooley, Gary Maartens, Paolo Denti

Summary: Rifabutin may serve as an alternative to rifampicin in co-administration with dolutegravir, as it does not require dose adjustment and can achieve the desired drug concentration.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2023)

Article Pharmacology & Pharmacy

Analysis of serum microRNA-122 in a randomized controlled trial of N-acetylcysteine for treatment of antituberculosis drug-induced liver injury

Muhammed Shiraz Moosa, Giusy Russomanno, Jeffrey R. Dorfman, Hannah Gunter, Chandni Patel, Eithne Costello, Dan Carr, Gary Maartens, Munir Pirmohamed, Christopher Goldring, Karen Cohen

Summary: This study investigated the concentrations of miR-122 in participants with antituberculosis drug-induced liver injury (AT-DILI) and its correlation with alanine aminotransferase (ALT) concentrations. The study found that miR-122 concentrations in AT-DILI patients were significantly higher than those in healthy volunteers and in patients on antituberculosis therapy without liver injury, and N-acetylcysteine (NAC) had no effect on miR-122 concentrations.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2023)

Article Immunology

Initial Supplementary Dose of Dolutegravir in Second-Line Antiretroviral Therapy: A Noncomparative, Double-Blind, Randomized Placebo-Controlled Trial

Ying Zhao, Rulan Griesel, Zaayid Omar, Bryony Simmons, Andrew Hill, Gert van Zyl, Claire Keene, Gary Maartens, Graeme Meintjes

Summary: This study evaluated the need for an initial dolutegravir dose adjustment in adults switching from first-line TEE treatment to TLD. The results showed that in patients with unsuppressed HIV-1 RNA levels and substantial baseline resistance to nucleoside reverse transcriptase inhibitors, a high proportion achieved virologic suppression without the need for an initial dolutegravir dose adjustment.

CLINICAL INFECTIOUS DISEASES (2023)

Article Immunology

A Phase 2A Trial of the Safety and Tolerability of Increased Dose Rifampicin and Adjunctive Linezolid, With or Without Aspirin, for Human Immunodeficiency Virus-Associated Tuberculous Meningitis: The LASER-TBM Trial

Angharad G. Davis, Sean Wasserman, Cari Stek, Mpumi Maxebengula, C. Jason Liang, Stephani Stegmann, Sonya Koekemoer, Amanda Jackson, Yakub Kadernani, Marise Bremer, Remy Daroowala, Saalikha Aziz, Rene Goliath, Louise Lai Sai, Thandi Sihoyiya, Paolo Denti, Rachel P. J. Lai, Thomas Crede, Jonathan Naude, Patryk Szymanski, Yakoob Vallie, Ismail Abbas Banderker, Muhammed S. Moosa, Peter Raubenheimer, Sally Candy, Curtis Offiah, Gerda Wahl, Isak Vorster, Gary Maartens, John Black, Graeme Meintjes, Robert J. Wilkinson

Summary: In this study, it was demonstrated that high-dose rifampicin and adjunctive linezolid is safe in adult HIV-associated tuberculous meningitis patients. Larger studies are needed to evaluate the potential toxicity of high-dose aspirin and its benefits on morbidity and mortality.

CLINICAL INFECTIOUS DISEASES (2023)

Article Infectious Diseases

The impact of enteral feeding and therapeutic monitoring of rifampicin with dose escalation in critically ill patients with tuberculosis

Rubeshan Perumal, Kogieleum Naidoo, Anushka Naidoo, Marothi P. Letsoalo, Aliasgar Esmail, Ivan Joubert, Paolo Denti, Lubbe Wiesner, Nesri Padayatchi, Gary Maartens, Keertan Dheda

Summary: This study investigates the pharmacokinetics of rifampicin and the impact of continuous enteral feeding on drug absorption in critically ill patients with tuberculosis. Therapeutic drug monitoring (TDM) with dose escalation is found to be an effective strategy to achieve target drug exposure in these patients.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2023)

Review Pharmacology & Pharmacy

Clofazimine for the treatment of tuberculosis

Jacob A. M. Stadler, Gary Maartens, Graeme Meintjes, Sean Wasserman

Summary: Shorter and fully oral regimens with new and repurposed drugs have become the first-choice treatment for drug-resistant tuberculosis. Clofazimine, a repurposed drug used in leprosy treatment, has shown promising results in treating drug-resistant tuberculosis. However, the safety, dosing considerations, adverse effects, and resistance mechanisms of clofazimine still need further research and evaluation.

FRONTIERS IN PHARMACOLOGY (2023)

Article Public, Environmental & Occupational Health

Mental Health, ART Adherence, and Viral Suppression Among Adolescents and Adults Living with HIV in South Africa: A Cohort Study

Andreas D. Haas, Raphael Lienhard, Christiane Didden, Morna Cornell, Naomi Folb, Tebatso M. G. Boshomane, Luisa Salazar-Vizcaya, Yann Ruffieux, Patience Nyakato, Anja E. Wettstein, Mpho Tlali, Mary-Ann Davies, Per von Groote, Milton Wainberg, Matthias Egger, Gary Maartens, John A. Joska

Summary: We conducted a study in a South African private-sector HIV program to assess adherence and viral suppression rates among adolescents and adults living with HIV. Participants with mental health diagnoses had poorer adherence patterns and a higher risk of viral non-suppression. Males, adolescents, and young adults also had an increased risk of viral non-suppression. Our findings emphasize the need for psychosocial interventions and improved mental health services in HIV treatment programs.

AIDS AND BEHAVIOR (2023)

Article Microbiology

Optimizing Moxifloxacin Dose in MDR-TB Participants with or without Efavirenz Coadministration Using Population Pharmacokinetic Modeling

M. T. Chirehwa, J. E. Resendiz-Galvan, R. Court, M. De Kock, L. Wiesner, N. de Vries, J. Harding, T. Gumbo, R. Warren, G. Maartens, P. Denti, H. McIlleron

Summary: In order to optimize dosing, the researchers investigated the pharmacokinetics and minimum inhibitory concentration (MIC) distribution of moxifloxacin in participants with multidrug-resistant tuberculosis (MDR-TB). Using nonlinear mixed-effects modeling and simulations, they analyzed plasma drug concentrations and clinical data to evaluate different dosing scenarios. The results showed that participants treated with efavirenz had increased clearance of moxifloxacin, resulting in reduced exposure. Simulations suggested that higher doses of moxifloxacin were needed to achieve target levels, particularly in heavier participants. The high-dose WHO regimen yielded more balanced exposures across different weight ranges. The safety of higher doses of moxifloxacin should be confirmed in clinical settings.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2023)

Letter Immunology

Cerebrospinal Fluid and Tuberculous Meningitis

Caryn M. Upton, Lubbe Wiesner, Kelly E. Dooley, Gary Maartens

CLINICAL INFECTIOUS DISEASES (2023)

Article Chemistry, Analytical

Liquid chromatography-tandem mass spectrometry analysis of delamanid and its metabolite in human cerebrospinal fluid using protein precipitation and on-line solid-phase extraction

Marian T. Mazanhanga, Anton Joubert, Sandra A. Castel, Marthinus van der Merwe, Gary Maartens, Kelly E. Dooley, Caryn M. Upton, Lubbe Wiesner

Summary: A liquid chromatography-tandem mass spectrometry method was developed and validated for the quantification of delamanid and its metabolite DM-6705 in human cerebrospinal fluid. The method was used to analyze cerebrospinal fluid samples from patients with pulmonary tuberculosis in a pharmacokinetic study.

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2023)

Article Biotechnology & Applied Microbiology

Pharmacogenetics of tenofovir renal toxicity in HIV-positive Southern Africans

Somila Mateza, Yuki Bradford, Gary Maartens, Simiso Sokhela, Nomathemba C. Chandiwana, Willem D. F. Venter, Frank A. Post, Marylyn D. Ritchie, David W. Haas, Phumla Sinxadi

Summary: Polymorphisms in the ABCC4 gene were found to be associated with changes in estimated glomerular filtration rate (eGFR) and urine beta 2-microglobulin/creatinine levels among HIV-positive individuals in South Africa. A polymorphism in the COL27A1 gene was also significantly associated with changes in eGFR.

PHARMACOGENETICS AND GENOMICS (2023)

Editorial Material Infectious Diseases

Weight gain on dolutegravir: Association is not the same as causation

Gary Maartens, Phumla Sinxadi, W. D. Francois Venter

SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE (2023)

Article Pharmacology & Pharmacy

Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population

Aida N. Kawuma, Roeland E. Wasmann, Phumla Sinxadi, Simiso M. Sokhela, Nomathemba Chandiwana, Willem D. F. Venter, Lubbe Wiesner, Gary Maartens, Paolo Denti

Summary: TDF and TAF are prodrugs of tenofovir used to inhibit HIV replication. TDF converts to tenofovir in plasma and may cause toxicity, while TAF converts to tenofovir intracellularly and can be administered at lower doses. Limited data exist on the use of TAF in Africa.

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2023)

Article Medical Laboratory Technology

Validation of a quantitative multiplex LC-MS/MS assay of carvedilol, enalaprilat, and perindoprilat in dried blood spots from heart failure patients and its cross validation with a plasma assay

Andre Joubert, Anton Joubert, Marthinus van der Merwe, Jennifer Norman, Sandra Castel, Paolo Denti, Karen Sliwa, Gary Maartens, Phumla Sinxadi, Lubbe Wiesner

Summary: This study validated an LC-MS/MS method for quantifying carvedilol, enalaprilat, and perindoprilat in DBS, and evaluated its feasibility as an adherence determining assay. The method was further clinically validated through a pharmacokinetic pilot study, showing that DBS and plasma concentrations can be used interchangeably. The results suggest that the assay is suitable for assessing adherence to carvedilol and perindoprilat, as well as enalaprilat.

JOURNAL OF MASS SPECTROMETRY AND ADVANCES IN THE CLINICAL LAB (2023)

Article Multidisciplinary Sciences

Validation of a quantitative liquid chromatography tandem mass spectrometry assay for linezolid in cerebrospinal fluid and its application to patients with HIV-associated TB-meningitis

Marian Mazanhanga, Anton Joubert, Sandra Castel, Marthinus Van de Merwe, Gary Maartens, Sean Wasserman, Lubbe Wiesner

Summary: A simple and quick method was developed to analyze linezolid in cerebrospinal fluid of patients with tuberculous meningitis, and its accuracy and precision were validated. The concentration of linezolid in cerebrospinal fluid varied in patients and was not significantly affected by the filtration process.

HELIYON (2023)

No Data Available